News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Study Highlights Importance of Progression-Related End Points in Cancer

Mar 23, 2020
Matthew Fowler

This study examined the association of disease progression and the deterioration of health-related quality of life for patients with metastatic breast, pancreatic, lung, and colorectal cancer.

Patients with metastatic breast, pancreatic, lung, and colorectal cancer saw disease progression associated with deteriorating health-related quality of life, according to a recent study published in JAMA Network Open.

Global health-related quality of life was most associated with lung cancer (6.7 points [95% CI, 3.5-9.9 points]; P< .001) and pancreatic cancer (5.4 points [95% CI, 3.3-7.5 points]; P< .001). The association was least pronounced in colorectal cancer (3.5 points [95% CI, 1.3-5.7 points]; P= .002) and breast cancer (2.4 points [95% CI, 1.0-3.9 points]; P = .001).

“The objective of this analysis was to determine the association of disease progression with various health-related quality of life domains in patients with 1 of 4 frequent cancers in clinical routine practice,” wrote the researchers. “The findings suggest that disease progression is associated with a deterioration in health-related quality of life, irrespective of the cancer entity.”

The study also concluded that the first disease progression was associated with a statistically significant deterioration in 37 of the 45 health-related quality of life scales. Even more, 17 of those 37 saw results that were clinically meaningful. Appetite, physical functioning, and fatigue were impacted the most, regardless of cancer type. The second progression saw even further health-related quality of life deterioration.

The researchers used over 8000 questionnaires from 2314 patients with 2562 documented disease progressions. Of those patients, 464 had breast cancer, 807 had pancreatic cancer, 341 had lung cancer, and 702 had colorectal cancer.

The 4 validated questionnaires were the Functional Assessment of Cancer Therapy–General version 4, European Organization for Research and Treatment of Cancer QLQ-C30 version 3.0, European Organization for Research and Treatment of Cancer QLQ-C15-PAL version 1, and Hospital Anxiety and Depression Scale

“Regardless of whether the cancer was originating from breast, pancreas, lung, or colon, disease progression was adversely associated with health-related quality of life in this real-world setting,” the researchers explained. “Looking at the deterioration in global health-related quality of life upon the first disease progression, with 2.5 points in breast cancer and 3.5 points in colorectal cancer, the deterioration was markedly higher in pancreatic cancer (5.4 points) and lung cancer (6.7 points). This difference may well be associated with the differing prognoses and tumor biological profiles of these entities.”

As for some limitations to the study, the researchers start with the lack of “specifications as to the timing, frequency, or criteria of tumor assessment” due to observational nature of the study design. A second limitation frequently seen in these types of studies is missing data. Patients who find their health-related quality of life deteriorating are typically less likely to report their data, according to the researchers.

Moving forward, the researchers hope this study provides context on the importance of disease progression from the patient perspective. Therefore, progression-related end points should also be considered in these types of cancers when evaluating the benefit of novel treatment.

“This evidence highlights the importance of progression-related end points, such as time to progression and progression-free survival, as additional patient-relevant end points when evaluating the benefit of new treatments for patients with metastatic cancer,” wrote the researchers.

Reference:

Marschner N, Zacharias S, Lordick F, et al. Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer. JAMA Network Open. doi:10.1001/jamanetworkopen.2020.0643.

Related Videos
Experts on colorectal cancer
Arvind Dasari, MD, MS, an expert on colorectal cancer
Experts on colorectal cancer
Experts on colorectal cancer
Experts on colorectal cancer
Arvind Dasari, MD, MS, an expert on colorectal cancer
Arvind Dasari, MD, MS, an expert on colorectal cancer
Experts on colorectal cancer
Experts on colorectal cancer
Experts on colorectal cancer
Related Content

Dalpiciclib Combo Improves PFS Vs Placebo in HER2– Advanced Breast Cancer

May 29th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

Expanding Medicaid May Mitigate Disparities in Pancreatic/Gastric Cancers  

May 26th 2023

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023

NCCN Guidelines Recommend Use of FES PET Imaging in ER+ Breast Cancer

May 26th 2023

Breast Cancer Survivors May Benefit From Phone-Based Weight Loss Program 

May 25th 2023

Dalpiciclib Combo Improves PFS Vs Placebo in HER2– Advanced Breast Cancer

May 29th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

Expanding Medicaid May Mitigate Disparities in Pancreatic/Gastric Cancers  

May 26th 2023

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023

NCCN Guidelines Recommend Use of FES PET Imaging in ER+ Breast Cancer

May 26th 2023

Breast Cancer Survivors May Benefit From Phone-Based Weight Loss Program 

May 25th 2023

Dalpiciclib Combo Improves PFS Vs Placebo in HER2– Advanced Breast Cancer

May 29th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

Expanding Medicaid May Mitigate Disparities in Pancreatic/Gastric Cancers  

May 26th 2023

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023

NCCN Guidelines Recommend Use of FES PET Imaging in ER+ Breast Cancer

May 26th 2023

Breast Cancer Survivors May Benefit From Phone-Based Weight Loss Program 

May 25th 2023
Related Content

Findings from the phase 3 DAWNA-2 trial suggest that dalpiciclib plus endocrine therapy may be a potential novel first-line treatment option for hormone receptor–positive, HER2-negative advanced breast cancer.

Dalpiciclib Combo Improves PFS Vs Placebo in HER2– Advanced Breast Cancer

May 29th 2023
Article

Findings from the phase 3 DAWNA-2 trial suggest that dalpiciclib plus endocrine therapy may be a potential novel first-line treatment option for hormone receptor–positive, HER2-negative advanced breast cancer.


Rakhshanda Rahman, MD, FRCS, FACS, emphasizes educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023
Podcast

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.


Medicaid expansion may help overcome inequities in access to care for pancreatic and gastric cancers, with notable benefit in Black patients, according to an expert from The University of Texas MD Anderson Cancer Center.

Expanding Medicaid May Mitigate Disparities in Pancreatic/Gastric Cancers  

May 26th 2023
Article

Medicaid expansion may help overcome inequities in access to care for pancreatic and gastric cancers, with notable benefit in Black patients, according to an expert from The University of Texas MD Anderson Cancer Center.


Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023
Podcast

Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.


18F-Fluorestradiol is currently the only imaging agent approved by the FDA for assessing estrogen receptor–positive lesion status to better guide treatment decision-making.

NCCN Guidelines Recommend Use of FES PET Imaging in ER+ Breast Cancer

May 26th 2023
Article

18F-Fluorestradiol is currently the only imaging agent approved by the FDA for assessing estrogen receptor–positive lesion status to better guide treatment decision-making.


Data from a phase 3 study indicate that weight loss intervention with a telephone-based program appears to be effective across all subgroups of breast cancer survivors.

Breast Cancer Survivors May Benefit From Phone-Based Weight Loss Program 

May 25th 2023
Article

Data from a phase 3 study indicate that weight loss intervention with a telephone-based program appears to be effective across all subgroups of breast cancer survivors.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.